Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Randomized controlled trials to assess therapies for multiple sclerosis.

Dean M Wingerchuk1, John H Noseworthy

  • 1Department of Neurology, Mayo Clinic and Mayo Foundation, Scottsdale, AZ 55905, USA.

Neurology
|April 24, 2002
PubMed
Summary

Investigating multiple sclerosis (MS) therapies faces challenges like disease complexity and unpredictable courses. Optimizing clinical trial methods and developing better outcome measures are crucial for faster discovery of effective treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

JAMA neurology·2026
Same author

Psychiatric comorbidities cluster early after onset in MOGAD: a cross-sectional comparative study with MS and NMOSD.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Cerebellar Involvement in Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2024
Same author

Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.

The Lancet. Neurology·2024
Same author

MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: Yes.

Multiple sclerosis (Houndmills, Basingstoke, England)·2024
Same author

Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.

Annals of neurology·2023

Area of Science:

  • Neurology
  • Clinical Trials
  • Pharmacology

Background:

  • Multiple sclerosis (MS) presents significant challenges for clinical research due to its chronic nature, unpredictable progression, and heterogeneity.
  • Understanding MS pathophysiology remains limited, complicating the development and testing of new therapies.

Purpose of the Study:

  • To review the challenges in conducting clinical trials for multiple sclerosis therapies.
  • To highlight the importance of optimizing trial methodologies and surrogate endpoints for future drug development.

Main Methods:

  • The study reviews existing literature and methodologies used in randomized controlled trials (RCTs) for MS therapies.
  • It discusses limitations of current RCTs and proposes areas for improvement in trial design and data analysis.

Related Experiment Videos

Main Results:

  • RCTs have successfully demonstrated the efficacy of type 1 interferons and glatiramer acetate in altering the short-term course of MS.
  • Key challenges include disease chronicity, heterogeneity, unpredictable course, and limitations in surrogate endpoints for long-term disability.

Conclusions:

  • Optimizing MS clinical trial methodology, including the development of predictive surrogate endpoints, is essential to accelerate the discovery of effective therapies.
  • Addressing limitations such as cost, patient withdrawal, and sample size requirements through collaboration and innovative data utilization is critical for future progress.